Moss Adams Wealth Advisors LLC Acquires 529 Shares of Eli Lilly and Company (NYSE:LLY)

Moss Adams Wealth Advisors LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 72.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,259 shares of the company’s stock after acquiring an additional 529 shares during the quarter. Moss Adams Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $734,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of LLY. Lipe & Dalton purchased a new position in shares of Eli Lilly and Company in the 4th quarter worth about $26,000. Thompson Investment Management Inc. bought a new stake in Eli Lilly and Company in the third quarter worth about $27,000. Optiver Holding B.V. bought a new stake in Eli Lilly and Company in the third quarter worth about $36,000. Family CFO Inc purchased a new position in Eli Lilly and Company in the third quarter valued at about $40,000. Finally, O Brien Wealth Partners LLC grew its position in shares of Eli Lilly and Company by 70.5% during the 4th quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock valued at $44,000 after acquiring an additional 31 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

LLY stock traded down $2.77 during midday trading on Wednesday, reaching $775.00. The company had a trading volume of 2,010,705 shares, compared to its average volume of 3,076,480. The firm has a 50-day moving average price of $761.22 and a 200-day moving average price of $674.88. The company has a market capitalization of $736.56 billion, a P/E ratio of 114.14, a P/E/G ratio of 1.45 and a beta of 0.37. Eli Lilly and Company has a 1 year low of $419.80 and a 1 year high of $800.78. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company’s revenue was up 26.0% on a year-over-year basis. During the same period in the prior year, the company earned $1.62 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 13.82 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Thursday, May 16th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date is Wednesday, May 15th. Eli Lilly and Company’s payout ratio is presently 76.58%.

Analyst Ratings Changes

LLY has been the topic of several research analyst reports. Truist Financial upped their price objective on Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. Barclays boosted their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. BMO Capital Markets boosted their price target on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. Finally, TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $757.95.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.